Ascendis Pharma A/S (ASND) Stock Analysis
Latest ClaritX AI analysis ·
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding
| Metric | Value |
|---|---|
| Price | $227.87 |
| Market cap | $14.2B |
| Sector | Healthcare |
| Industry | Biotechnology |
| ClaritX AI score | 81/100 |
| Price/Book | 9.12 |
| Beta | 0.37 |
AI verdict
Ascendis Pharma A/S (ASND) presents a highly asymmetric, deep-value investment thesis defined by absolute fundamental supremacy clashing directly with intense, yet localized, technical friction. Currently trading at $227.87, the asset is situated precisely 19.24% below its 52-week high of $282.15. By shedding nearly 20% of its top-side premium, the euphoric risk associated with momentum chasing has been surgically purged. A stock trading at its 52-week high on blind retail hype is an inherently different risk proposition than a beaten-down asset boasting elite fundamentals. Trapped beneath its 200-day SMA ($235.56) with the RSI plunging to an extreme 26.78, the stock is experiencing severe mechanical oversold exhaustion. However, with an ultra-low beta of 0.372, this localized volatility is fundamentally decoupled from systemic macroeconomic risk, insulating investors from broader market drawdowns. Beneath this short-term technical weakness lies an undeniable financial juggernaut. Boasting a flawless 90.19% gross profit margin, a 71.69% net margin, and an incredibly cheap 16.82 P/E ratio, the valuation is drastically dislocated from its hyper-profitable commercial reality. Wall Street consensus aggressively projects $300 to $325 target prices, validating the belief that reclaiming global rights to the TransCon obesity pipeline is a massive long-term catalyst. Bolstered by a newly authorized $400 million share buyback that acts as a structural liquidity floor, Ascendis is uti
What this score has been worth
ClaritX scores ASND 81 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 189 analyses that scored in the 80-84 band, the average forward return was -1.2% with a 41% win rate, -6.3pp against the S&P 500. That is a measured tendency across many names, not a forecast for ASND — roughly 59% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.